A novel brain penetrant c-Abl tyrosine kinase inhibitor: Paving a path forward to success in disease modification in Parkinson's disease

Parkinsonism Relat Disord. 2023 Mar:108:105325. doi: 10.1016/j.parkreldis.2023.105325. Epub 2023 Feb 16.

Authors

Tanya Simuni¹, Kalpana Merchant²

Affiliations

¹ Department of Neurology Northwestern University Feinberg School of Medicine, 710 North Lake Shore Drive, 1126, Chicago, IL, 60611, USA. Electronic address: tatyana.simuni@nm.org.
² Department of Neurology Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, 303 E. Chicago Ave, USA. Electronic address: kalpana.merchant@northwestern.edu.

PMID: 36809869
DOI: 10.1016/j.parkreldis.2023.105325

No abstract available

Publication types

Editorial

MeSH terms

Brain / metabolism
Humans
Parkinson Disease*
Phosphorylation
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-abl / metabolism
Tyrosine Kinase Inhibitors

Substances

Tyrosine Kinase Inhibitors
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-abl